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Abstract
Background: Troponin I is a widely used and reliable marker 
of myocardial damage and its levels are routinely measured 
in acute stroke care. So far, the influence of troponin I eleva-
tions during hospital stay on functional outcome in patients 
with atraumatic intracerebral hemorrhage (ICH) is unknown. 
Methods: Observational single-center study including con-
servatively treated ICH patients over a 9-year period. Pa-
tients were categorized according to peak troponin I level 
during hospital stay (≤0.040, 0.041–0.500, > 0.500 ng/mL) 
and compared regarding baseline and hematoma character-
istics. Multivariable analyses were performed to investigate 
independent associations of troponin levels during hospital 
stay with functional outcome – assessed using the modified 
Rankin Scale (mRS; favorable 0–3/unfavorable 4–6) – and 
mortality after 3 and 12 months. To account for possible con-
founding propensity score (PS)-matching (1: 1; caliper 0.1) 
was performed accounting for imbalances in baseline char-
acteristics to investigate the impact of troponin I values on 
outcome. Results: Troponin elevations (> 0.040 ng/mL) dur-
ing hospital stay were observed in 308 out of 745 (41.3%) 
patients and associated with poorer status on admission 
(Glasgow Coma Scale/National Institute of Health Stroke 
Scale). Multivariable analysis revealed troponin I levels dur-
ing hospital stay to be independently associated with unfa-
vorable outcome after 12 months (risk ratio [95% CI]: 1.030 
[1.009–1.051] per increment of 1.0 ng/mL; p = 0.005), but not 
with mortality. After PS-matching, patients with troponin I 
elevation (≥0.040 ng/mL) versus those without had a signifi-
cant higher rate of  unfavorable outcome after 3 and 12 
months (mRS 4–6 at 3 months: < 0.04 ng/mL: 159/265 [60.0%] 
versus ≥0.04 ng/mL: 199/266 [74.8%]; p < 0.001; at 12 months: 
< 0.04 ng/mL: 141/248 [56.9%] versus ≥0.04 ng/mL: 179/251 
[71.3%]; p = 0.001). Conclusions: Troponin I elevations dur-
ing hospital stay occur frequently in ICH patients and are in-
dependently associated with functional outcome after 3 and 
12 months but not with mortality. © 2018 S. Karger AG, Basel
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Introduction
Patients with intracerebral hemorrhage (ICH) show 
1-year mortality rates up to 60% [1]. Several complica-
tions such as intraventricular hemorrhage (IVH), acute 
hydrocephalus, early hematoma expansion, and peri-
hemorrhagic edema may occur during hospital stay and 
have been previously verified to independently impact 
outcome [2–6]. In addition, recent studies reported a 
high rate of cardiac complications presumably linked to 
a further increase in mortality of patients with intracra-
nial hemorrhage [7–10].
Troponin I is a widely used and reliable marker of 
myocardial damage and its levels are routinely measured 
in acute stroke care. While several studies observed fre-
quently elevated troponin levels and electrocardiograph-
ic abnormalities and their independent associations with 
mortality and functional outcome in patients with sub-
arachnoid hemorrhage [8, 11, 12], the importance of tro-
ponin in patients with ICH is relatively unestablished. In 
one small study, elevated troponin I levels on admission 
were evident in roughly 20% of ICH patients and associ-
ated with higher rates of in-hospital mortality, yet meth-
odological shortcomings partly undermined that conclu-
sion [10]. In another analysis of surgically evacuated ICH 
patients, troponin levels on admission and post-sur-
gery were associated with in-hospital mortality [9]. Given 
these uncertainties, we systematically assessed the natural 
course of troponin levels in non-surgical ICH patients 
and – using appropriate statistical approaches to account 
for confounding – explored the influence of troponin lev-
els during hospital stay on clinical outcomes.
Methods
Patient Selection
All consecutive patients with atraumatic ICH admitted be-
tween 2006 and 2014 to the Department of Neurology, Friedrich-
Alexander University Erlangen-Nuremberg (FAU), Erlangen, 
Germany, were collected in a prospective longitudinal institution-
al database and is part of the UKER-ICH registry, which was 
 approved by the local Ethics Committee and institutional re-
view  board (Friedrich-Alexander-University Erlangen-Nurem-
berg, Germany, 115_17B). Informed consent was obtained by all 
patients or their closest relatives/legal representatives included in 
this study. Patients with secondary ICH due to hemorrhagic trans-
formation of tumor or ischemic stroke, ruptured aneurysm, or 
bleeding of arteriovenous malformation were excluded. This anal-
ysis focused on those patients only with available data on troponin-
levels during hospital stay, without surgical hematoma evacua-
tion and without myocardial infarction or stroke 6 weeks prior to 
ICH (Fig. 1).
Clinical Parameters
We assessed data on demographic parameters (age, sex), prior 
medical history (i.e., prior myocardial infarction and stroke), clin-
ical and radiological status on admission (Glasgow Coma Scale 
[GCS], National Institute of Health Stroke Scale [NIHSS]) as well 
as laboratory data. According to our institution’s protocol, tropo-
nin I levels were measured on admission in the emergency depart-
ment and at least once within 72 h after admission to detect myo-
cardial damage. All serial troponin levels during hospital stay were 
integrated into our database after reviewing the patient’s medical 
charts and institutional laboratory databases. According to our lab-
oratory’s standards and to the manufacturer of the measuring de-
vice, troponin I levels were interpreted as normal (troponin ≤ 0.040 
ng/mL), as cardiovascular syndrome (troponin 0.040–0.500 ng/
mL), or as manifest myocardial infarction (> 0.500 ng/mL) [13]. All 
troponin levels were assessed using a chemiluminescent immuno-
assay for quantitative determination of cardiac troponin I (AccuT-
nI from Beckmann Coulter; https://www.beckmancoulter.com).
Imaging
Diagnosis of ICH was made upon CT imaging (SIEMENS 
 Somatom Volume Zoom, Somatom Sensation 64, Somatom Defi-
nition AS+) or magnetic resonance tomography (SIEMENS Mag-
netom Sonata 1.5T, Magnetom Aera 1.5). Two neuroradiologists 
blinded to clinical data scored ICH location, estimated the hemor-
rhage volume using ABC methods [14] and documented the pres-
ence and extent of IVH [15]. Hemorrhage enlargement was scored 
if ICH volume on follow-up imaging exceeded 33% compared to 
initial imaging [16].
Outcome Measures
Functional outcome was assessed using the modified Rankin 
Scale (mRS) after 3 and 12 months by either mailed questionnaires 
or semi-structured telephone interviews performed by physicians 
certified for stroke outcome assessments [17]. In case of patients’ 
readmissions, we documented the mRS-score assessed by a physi-
cian at the hospital of treatment. Favorable outcome was defined 
as mRS = 0–3 and unfavorable outcome as mRS = 4–6 [18]. 
Primary outcome of this study was the proportion of patients 
with favorable functional outcome 12 months after ICH catego-
rized according to the peak troponin I during hospital stay. Sec-
ondary outcomes comprised the proportion of patients with favor-
able functional outcome at 3 months as well as mortality rates at 3 
and 12 months.
Statistical Analyses
All statistical analyses were performed using SPSS (IBM, SPSS 
Statistics 22) and R 3.12 (r-project.org). For analysis of baseline 
characteristics, patients were initially categorized according to 
peak troponin I values during hospital stay (≤ 0.040, 0.040–0.500, 
and >0.500 ng/mL). The significance level was set at α = 0.05 and 
both-sided statistical tests were performed. Nominal data were 
compared using chi-square or Fisher’s exact test. For comparison 
among those groups, analysis of variance and Kruskal-Wallis test 
were performed dependent on mode of data distribution. All pa-
rameters showing a statistical trend in univariate analysis were in-
cluded in a multivariate regression model (log Poisson with robust 
estimator) to identify parameters being independently associated 
with primary and secondary outcomes. Further, subanalyses were 
performed for (i) for patients without comorbidities affecting tro-
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ponin-levels (known congestive heart failure or abnormal kidney 
function) and (ii) for patients with normal troponin-levels on ad-
mission (troponin I ≤ 0.040 ng/mL) who developed a troponin el-
evation during hospital stay. Troponin elevations were categorized 
in the latter group according to the peak troponin I level mea-
sured at hospital into modest (peak troponin I between 0.040 and 
0.500 ng/mL) and severe elevation (peak troponin I equal or great-
er than 0.500 ng/mL). 
Further, receiver operating characteristics analysis was per-
formed to investigate associations of peak troponin levels during 
hospital stay with the primary outcome to determine the best cut-
off value for its prediction [19]. Subsequently, patients were di-
chotomized according to the identified cutoff value and compared 
using Student t test for normally and Mann-Whitney U test for 
non-normally distributed data. To minimize bias by confounding, 
we performed propensity score (PS) matching (1: 1 match, caliper 
0.1) to adjust for imbalances of clinically relevant parameters dif-
fering among the dichotomized groups [20]. Analyses of primary 
and secondary outcomes were based on the propensity score 
matched cohorts.
Cohort from 2006 to 2014
811 patients with spontaneous ICH
Trop ≤0.040 ng/mL
Trop <0.04 ng/mL
Trop 0.041–0.5 ng/mL Trop >0.5 ng/mL
Trop ≥0.04 ng/mL
1:1 propensity-score match
437 available for
 outcome analysis
431 at 3 months
410 at 12 months
225 available for
 outcome analysis
222 at 3 months
214 at 12 months
83 available for
 outcome analysis
83 at 3 months
76 at 12 months
269 available for
 outcome analysis
265 at 3 months
248 at 12 months
269 available for
 outcome analysis
266 at 3 months
251 at 12 months
Primary endpoint
 - Unfavorable outcome (mRS = 4–6) after 12 months
Secondary endpoints
 - Mortality after 12 months
 - Unfavorable outcome after 3 months
 - Mortality after 3 months
745 patients with spontaneous ICH available for
analysis of primary and secondary outcomes
66 patients excluded
- 35 no troponin levels available
- 24 surgical hematoma evacuation
- 7 MI/ischemic stroke within 6 weeks
Subclassification according to 
peak troponin level during hospital stay 
Fig. 1. Flowchart of patients. Over 9 years, 
811 patients with ICH were identified. Af-
ter exclusion of 38 patients because of miss-
ing troponin I values, 24 because of surgical 
hematoma evacuation, and 7 because of MI 
or ischemic stroke within 6 weeks prior in-
dex ICH, 745 patients with spontaneous 
conservatively ICH were available for anal-
yses. For outcome analysis, patients were 
categorized according to the peak troponin 
I level during hospital stay. Further sub-
classification was undertaken according to 
the best discriminative cutoff value identi-
fied in ROC-analysis (see online suppl. Fig. 
I). ICH, intracerebral hemorrhage; MI, 
myocardial infarction; PS, propensity 
score; ROC, receiver operating characteris-
tics. 
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Results
Figure 1 shows the study design. Over a 9-year pe-
riod, a total of 811 patients participated in our longitu-
dinal database. After exclusion of 35 patients because of 
missing troponin I values, 24 because of surgical hema-
toma evacuation and 7 because of myocardial infarc-
tion or ischemic stroke 6 weeks prior to index ICH, 745 
patients remained for final analysis (Fig.  1). Patients 
were grouped according to the peak troponin I level ei-
ther (i) remaining ≤0.040 ng/mL during the entire hos-
pital stay (n = 437/745; 58.7%), (ii) ranging between 
0.040 and 0.500 ng/mL (n = 225/745; 30.2%), and (iii) 
exceeding > 0.500 ng/mL (n = 83/745; 11.1%; see Meth-
ods and Table 1).
Patient Characteristics and Natural Course  
of Troponin I
Table 1 provides an overview of clinical and neuro-
radiological characteristics of ICH patients accord-
ing  to the abovementioned classification. While 
there  were no differences in patient demographics, 
with  increasing troponin category, we observed (i) 
higher rates of comorbidity (prior to congestive 
heart failure or  abnormal kidney function), (ii) poorer 
clinical status on  admission, (iii) more often ICH in 
deep location, and (iv) a higher rate of IVH (Table 1). 
Whereas neither ICH volume nor the proportion of 
 patients with hematoma enlargement was significant-
ly  differing among all groups, unadjusted functional 
outcomes at discharge were in unfavor of increas-
ing troponin levels (Table 1). These differences in clin-
ical status  on admission and hematoma characteris-
tics  remained significant after exclusion of patients 
with prior comorbidities possibly confounding tropo-
nin I  levels, such as known congestive heart failure 
or  abnormal kidney function (online suppl. Table 1; for 
all online suppl. material, see www.karger.com/
doi/10.1159/000492395). 
The natural course of troponin I levels during acute 
stay is illustrated in Figure 2. While on admission 522 
out of 639 (81.7%) had no troponin elevation (≤0.04 ng/
mL), on day 3, almost every second patient showed in-
creased troponin levels (≤0.04 ng/mL: 111/201 [55.2%] 
versus > 0.04 ng/mL 90/201 [44.8%]). In patients with 
troponin levels between 0.040 and 0.500 ng/mL tropo-
nin levels were highest at day 2 (median [interquartile 
range (IQR)] at day 2: 0.060 [0.040–0.110]). In patients 
with peak troponin levels greater 0.500 ng/mL, troponin 
levels were highest at day 4 (median [IQR] at day 4: 0.895 
[0.165–1.948]; Fig. 2). In the latter group, the median 
peak troponin level during hospital stay was 1.60 (IQR 
0.82–4.82) ng/mL (Table 1).
Association of Peak Troponin Levels with  
Functional Outcome
To explore associations of troponin I levels with pri-
mary and secondary outcomes, we in a first step performed 
multivariable regression analyses to identify parameters 
independently related to outcome measures. Regarding 
the primary outcome, next to established parameters such 
as age, hematoma volume, IVH and NIHSS, peak troponin 
I levels during hospital stay were independently associated 
with unfavorable outcome at 12 months (mRS 4–6 after 
12 months: risk ratio [95% CI]: 1.030 [1.009–1.051]; per 
increment of 1.0 ng/mL; p = 0.005; Table 2) but not with 
mortality after 3 and 12 months (online suppl. Table 2a, c). 
Further analysis of patients with normal troponin-values 
on admission revealed troponin elevations during hospi-
tal  stay to be independently associated with unfavorable 
outcome at 12 months (risk ratio [95% CI]: modest eleva-
tion 1.261 [1.100–1.446], p = 0.001; severe elevation 1.326 
[1.063–1.654], p = 0.012; online suppl. Table 3).
In light of the independent association of peak troponin 
levels with functional outcome, we performed receiver op-
erating characteristics-analysis to identify the best discrim-
inate threshold predisposing unfavorable outcome (online 
suppl. Fig. 1). Graphical regression analysis revealed a true-
positive significant association of both troponin levels on 
admission as well as peak troponin levels with unfavorable 
outcome after 12 months (AUC [95% CI]: troponin on ad-
mission 0.616 [0.571–0.662]; p < 0.001; peak troponin: 
0.627 [0.581–0.673]; p < 0.001) with a best discriminative 
threshold of peak troponin levels of ≥0.04 ng/mL during 
hospital stay (Youden index: 0.238; sensitivity 59.0%; specif-
ity 67.5%). Interestingly, this statistical determined cutoff 
point was very close to our laboratory’s threshold for car-
diovascular syndrome (defined as troponin I > 0.04 ng/mL).
Dichotomizing our study cohort into patients with the 
identified cutoff threshold troponin I levels < 0.04 vs. 
≥0.04 ng/mL during hospitalization revealed significant 
and relevant imbalances (comorbidity, clinical, and ra-
diological ICH severity) in baseline characteristics in un-
favor of patients with increased troponin I levels (Ta-
ble 3a). To investigate the clinical significance of elevated 
troponin I levels ≥0.04 ng/mL – accounting for this con-
founding – we performed propensity score matching 
to  achieve 1: 1 evenly balanced cohorts (each n = 269) 
available for analysis of primary and secondary outcomes 
(Table 3b).
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Table 1. Characteristics of ICH patients according to peak troponin level during hospital stay
Patients with spontaneous ICH 
(n = 745)
Troponin
≤0.040 ng/mL
(n = 437)
Troponin
0.040–0.500 ng/mL
(n = 225)
Troponin
>0.500 ng/mL
(n = 83)
p value
Age, years, median (IQR) 74 (65–80) 72 (61–80) 70 (57–78) 0.107
Gender, female, n (%) 220 (50.3) 99 (44.0) 36 (43.4) 0.214
Prior comorbidities, n (%)
Premorbid mRS 1 (0–2) 1 (0–2) 0 (0–2) 0.137
Hypertension 357 (81.7) 188 (83.6) 74 (89.2) 0.245
Diabetes mellitus 123 (28.2) 54 (24.0) 24 (28.9) 0.471
Coronary artery disease 50 (13.1) 31 (15.0) 17 (23.3) 0.081
Congestive heart failure 46 (10.7) 32 (14.3) 22 (27.5) <0.001
Abnormal kidney function 41 (9.4) 41 (18.2) 19 (22.9) <0.001
Prior ischemic stroke 79 (18.2) 51 (22.7) 14 (16.9) 0.321
Prior hemorrhagic stroke/major bleeding 43 (9.9) 18 (8.0) 6 (7.2) 0.599
Prior myocardial infarction 52 (12.0) 34 (15.1) 17 (20.5) 0.102
Antiplatelet medication 137 (31.4) 69 (30.8) 27 (32.5) 0.958
Oral anticoagulation 56 (12.8) 19 (8.4) 10 (12.0) 0.241
Admission status, median (IQR)
GCS 13 (8–15) 12 (3–14) 11 (3–13) <0.001
NIHSS 11 (5–22) 17 (9–32) 19 (11–32) <0.001
ICH score 1 (0–2) 2 (1–3) 2 (1–3) <0.001
Initial imaging
ICH volume, cm³, median (IQR) 13.7 (4.8–39.6) 16.1 (6.1–40.7) 14.1 (6.3–32.9) 0.672
IVH, n (%) 182 (41.6) 153 (68.0) 51 (61.4) <0.001
GRAEB score, median (IQR) 0 (0–4) 2 (0–6) 1 (0–6) <0.001
Location, n (%)
Deep 178 (40.7) 114 (50.7) 56 (67.5) <0.001
Lobar 219 (50.1) 77 (34.2) 15 (18.1) <0.001
Cerebellar 25 (5.7) 23 (10.2) 7 (8.4) 0.103
Brainstem 14 (3.2) 11 (4.9) 5 (6.0) 0.308
Left-hemispheric 229 (52.6) 125 (55.6) 44 (53.0) 0.772
Hematoma enlargement, n (%) 42 (/12.2) 21 (11.2) 9 (12.2) 0.936
Treatment, n (%)
External ventricular drainage 99 (22.7) 102 (45.3) 38 (45.8) <0.001
Mechanical ventilation 142 (32.9) 135 (60.0) 63 (76.8) <0.001
Withdrawal of care <24 h 66 (15.1) 22 (9.8) 10 (12.0) 0.150
Initial laboratory parameters, median (IQR)
INR 1.03 (0.98–1.13) 1.04 (0.98–1.12) 1.04 (0.99–1.14) 0.570
Hemoglobin 13.7 (12.3–14.9) 13.7 (12.5–15.1) 14.1 (12.5–15.3) 0.650
Leucocytes 8.5 (6.8–10.8) 10.4 (7.9–13.4) 9.7 (7.7–13.0) <0.001
Creatinine 0.85 (0.69–1.03) 0.92 (0.73–1.16) 0.99 (0.71–1.26) 0.002
Estimated GFR 83 (66–102) 79 (59–102) 74 (58–95) 0.021
Troponin levels, ng/mL, median (IQR)
Troponin on admission 0.01 (0.01–0.02) 0.03 (0.02–0.08) 0.04 (0.02–0.10) <0.001
Peak troponin level 0.02 (0.01–0.03) 0.09 (0.06–0.17) 1.60 (0.82–4.82) <0.001
Outcome
At discharge, median (IQR) 4 (3–5) 5 (4–6) 5 (5–6) <0.001
mRS 0–3, n (%) 139 (31.8) 26 (11.6) 5 (6.0) <0.001
mRS 4–6, n (%) 298 (68.2) 199 (88.4) 78 (94.0) <0.001
Mortality, n (%) 97 (22.2) 57 (25.3) 22 (26.5) 0.538
All available ICH patients were categorized according to peak troponin I level during hospital stay in patients with troponin ≤0.040, 
0.041–0.500, and >0.500 ng/mL. Comparisons among the 3 groups were calculated using chi-square as well as Fisher test for nominal 
and analysis of variance as well as Kruskal-Wallis test for continuous parameters. Significant findings are expressed in bold. 
ICH, intracerebral hemorrhage; IVH, intraventricular hemorrhage; mRS, modified Rankin Scale (range 0, no deficit, to 6, death); GCS, 
Glasgow coma scale; NIHSS, National Institute of Health Stroke Scale; INR, international normalized ratio; IQR, interquartile range.
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Primary and Secondary Outcomes
The primary and secondary outcomes are displayed in 
Figure 3. As compared to patients with peak troponin I 
levels < 0.04 ng/mL, the proportion of patients with un-
favorable functional outcome at 12 months was signifi-
cantly increased in patients with peak troponin I levels 
≥0.04 ng/mL (mRS 4–6 at 12 months: < 0.04 ng/mL: 
141/248 [56.9%] versus ≥0.04 ng/mL: 179/251 [71.3%]; 
p = 0.001). Regarding secondary outcomes, as compared 
to patients with peak troponin I levels < 0.04 ng/mL, 
the proportion of patients with unfavorable functional 
outcome at 3 months was significantly increased in pa-
tients with peak troponin I levels ≥0.04 ng/mL (mRS 
4–6 at 3 months: < 0.04 ng/mL: 159/265 [60.0%] versus 
≥0.04 ng/mL: 199/266 [74.8%]; p < 0.001), yet mortali-
ty  rates did not differ among both groups neither at 
3 months nor at 12 months (Fig. 3). 
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Table 2. Multivariable analysis of parameters associated with functional outcome
Parameter Risk ratio (95% CI) p value
Age (per increment 1 year) 1.021 (1.017–1.026) <0.001
Initial NIHSS (per increment 1 point) 1.028 (1.023–1.034) <0.001
Initial ICH volume (per increment 1 cm³) 1.002 (1.001–1.003) <0.001
Initial Graeb score (per increment 1 point) 1.027 (1.013–1.041) <0.001
Peak troponin level during hospital course
(per increment 1.0 ng/mL) 1.030 (1.009–1.051) 0.005
Multivariable regression analysis (log Poisson) was calculated for the association with unfavorable outcome after 
12 months, defined as a score between 4 and 6 on the mRS. Only parameters have been included in multivariable mo-
del which were significant (p < 0.05) in prior univariate testing, that is, age, initial NIHSS, initial ICH volume, extent 
of IVH (Graeb Score) and peak troponin I level. Significant findings are expressed in bold.
Table 3. Characteristics of patients dichotomized to troponin threshold (0.04 ng/mL) before and after PS-matching
Patients with spontaneous ICH Troponin <0.04 ng/mL Troponin ≥0.04 ng/mL p value
a. Pre-PS match (n = 745) n = 376 n = 369
Age, years, median (IQR) 74 (65–80) 71 (61–80) 0.059
Gender, female, n (%) 192 (51.1) 163 (44.2) 0.060
Prior comorbidities, n (%)
Premorbid mRS 0 (0–2) 1 (0–2) 0.046
Congestive heart disease 40 (10.8) 60 (16.5) 0.025
Abnormal kidney function 30 (8.0) 71 (19.2) <0.001
Admission status, median (IQR)
GCS 14 (9–15) 12 (3–14) <0.001
NIHSS 10 (4–20) 18 (9–32) <0.001
Initial imaging
ICH volume, cm3, median (IQR) 16.6 (6.5–40.7) 12.4 (4.3–38.4) 0.031
GRAEB score, median (IQR) 0 (0–3) 2 (0–6) <0.001
Deep location, n (%) 153 (40.7) 195 (52.8) 0.001
b. Post-PS match (n = 538) n = 269 n = 269
Age, years, median (IQR) 74 (63–80) 73 (62–80) 0.774
Gender, female, n (%) 125 (46.5) 131 (48.7) 0.604
Prior comorbidities, n (%)
Premorbid mRS 1 (0–2) 1 (0–2) 0.579
Congestive heart disease 35 (13.0) 37 (13.8) 0.800
Abnormal kidney function 29 (10.8) 38 (14.1) 0.240
Admission status, median (IQR)
GCS 13 (6–15) 13 (8–14) 0.693
NIHSS 13 (6–25) 14 (8–23) 0.472
Initial imaging
ICH volume, cm³, median (IQR) 14.3 (4.4–43.4) 15.6 (5.5–40.1) 0.597
GRAEB score, median (IQR) 0 (0–5) 1 (0–5) 0.208
Deep location, n (%) 126 (46.8) 132 (49.1) 0.605
PS matching (caliper 0.1, ratio 1:1, nearest neighbor approach) was performed according to the following param-
eters: age, premorbid mRS, gender female, congestive heart disease, abnormal kidney function, GCS and NIHSS on 
admission, ICH volume on initial imaging, extent of IVH measured by Graeb score and deep location of ICH). After 
PS-matching 269 ICH patients with Troponin <0.04 ng/mL and 269 with troponin ≥0.04 ng/mL during hospital stay 
remained for outcome analysis.
GCS, Glasgow coma scale; NIHSS, National Institute of Health Stroke Scale; PS, propensity score; mRS, modi-
fied Rankin Scale score; ICH, intracerebral hemorrhage.
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Discussion
In this observational cohort of patients with spontane-
ous ICH, the elevation of troponin I levels during hospital 
stay occurred in almost every second patient and was as-
sociated with increased rates of unfavorable functional 
outcome both at 3 and 12 months, yet without affecting 
mortality at these time-points. Several aspects deserve at-
tention. 
In line with results of prior studies, elevated troponin 
levels on admission were frequently observed and evident 
in about 1 of 5 ICH patients [10]. Assessment of serial 
troponin I levels during hospital stay revealed a further 
increase in the rate of elevated troponin levels, a finding 
predominantly driven by increased ventricular involve-
ment. As reported previously for patients with subarach-
noid hemorrhage [21], elevation of troponin I levels may, 
on the one hand, result from intraventricular blood and, 
therefore, meningeal irritation, leading to strong system-
ic stress-responses [22, 23]. As a result, an enhanced re-
lease of catecholamines and consequently higher myocar-
dial stress may reflect a neurocardiac dysbalance, evident 
also after ICH, notably in those patients with intraven-
tricular involvement [21, 22, 24]. In addition, up to now, 
the longitudinal occurrence of troponin elevations in 
ICH patients was only insufficiently established and 
pathophysiological considerations further include an in-
crease of intracranial pressure additionally triggering 
sympathetic storms [10, 21, 24–26]. To protect patients 
with cerebrovascular diseases from this excessive stress, 
the use of beta-blockers is currently discussed [27, 28]; 
however, this treatment is currently not considered in 
current guidelines for ICH-patients [29]. 
Questions remain as to why patients with elevated tro-
ponin levels show worse functional outcome. Consider-
ing associations of elevated troponin levels with left-ven-
tricular dysfunction and systemic hypotonia in SAH-pa-
tients [8], observed differences in functional outcome 
may be based on an impaired blood and oxygen supply of 
the perihemorrhagic penumbra, that is, brain tissue sur-
rounding the ICH at high risk for secondary ischemic 
damage [30, 31]. Such secondary neurological deteriora-
tion may be driven by tolerating hypotensive blood pres-
sure values in ICH patients in order to primarily prevent 
hematoma enlargement [32]. Contrary to recent investi-
gations reporting higher rates of mortality in patients 
with elevated troponin levels on admission [10], we did 
not observe similar associations after applying sophisti-
cated statistical approaches to adjust for confounding 
[33–35]. It remains to be established whether the in-
creased rates of troponin I levels influenced functional 
outcomes by means of possible secondary cardiac com-
plications or if elevated troponin levels reflect an epiphe-
nomenon of increased comorbidity which – despite strict 
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Fig. 3. Distribution of modified Rankin 
Scale (mRS) in patients with troponin 
<0.04 vs. ≥0.04 ng/mL after PS-match-
ing.  Functional outcome at discharge, 3 
and 12 months is shown as mRS-plot for 
patients with troponin I values < 0.04 vs. 
≥0.04 ng/mL after  PS-matching (for de-
tailed procedure see  Table 3). Dashed lines 
separate each score on the mRS. The thick 
lines illustrate the proportion of patients 
with favorable (defined as mRS = 0–3) and 
unfavorable outcome (mRS = 4–6). p val-
ues were calculated for the comparison of 
unfavorable outcome among patients with 
troponin < 0.04 vs. ≥0.04 ng/mL at each 
time-point.
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statistical adjustments – exerted subliminally impact on 
outcome measures [36]. In ICH patients with pathologi-
cally increased troponin values, it seems reasonable to 
perform prompt cardiac work-up – including ECG, echo-
cardiography, and cardiac catheter examination, if appli-
cable – to differentiate between underlying structural car-
diac diseases and stress-induced cardiomyopathy and to 
consider feasible treatment approaches in those patients. 
Possibly, the prompt cardiac evaluation and consequent 
treatment of ICH patients with troponin elevations may 
improve the functional outcome of this patient cohort. In 
light of the findings presented here, it seems valuable to 
seek for a prospective analysis including longitudinal car-
diac assessments in order to verify the significance of el-
evated troponin I levels in patients with ICH. Ongoing 
studies will clarify the value of biomarkers, such as tropo-
nin, for the prediction of functional outcome in ICH pa-
tients and which patients may benefit from additional 
medical therapy ([37] and ClinicalTrials.gov Identifier: 
NCT02935985). 
This study has several limitations, notably its retrospec-
tive and monocentric design. Further, serial troponin as-
sessments during hospital stay – joined by electro- and 
echocardiographic findings – did not follow a priori de-
fined time-points, but were rather obtained based on indi-
vidual physicians’ discretions. As a result of this retrospec-
tive design, serial troponin measurements were not avail-
able in all patients, which may lead to the overestimation 
of troponin elevations during hospital stay in the presented 
cohort. Further, we did not specifically note the timing and 
amount of administered catecholamines and the occur-
rence and duration of cardiac arrhythmias. In addition, de-
spite adjustments residual confounding, notably response 
bias as a result of our outcome assessment, cannot be fully 
excluded and complications reported to be potentially as-
sociated with troponin elevations, such as cerebral hernia-
tion [38], were not specifically documented. Due to the 
exclusion of secondary causes of ICH, such as hemorrhag-
ic transformation or ruptured arteriovenous malforma-
tion, our findings cannot be applied to all subtypes of ICH-
patients.
Summary
In conclusion, elevated troponin I levels occur fre-
quently during hospital stay and are associated with func-
tional outcome after ICH. Further studies are needed to 
clarify pathophysiological mechanisms behind these ob-
servations and its clinical relevance in acute ICH.
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